Study to Test Effects and Safety of RO7568282 in Early Parkinson's Disease
US: FDA approval not reviewed here
The registry reports recruiting. This is trial metadata, not an assessment of treatment benefit.
Phase 2 · Enrolling participants
Planned enrollment: 474 participants
Study ages: 40 Years to 85 Years
Recruiting sites listed in: China, Ireland, Poland, United Kingdom, United States
No results-posting date in this record
Read trial record and resultsChecked Nov 16, 2026